Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingPriority Health Genetics Coverage & Prior Auth Upd…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedpriority healthPolicy N/A

    GENETICS: COUNSELING, TESTING, SCREENING

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Priority Health coverage criteria for genetic counseling, testing, and screening services, including medical necessity, prior authorization via Evicore for select tests, and management of specific tests; applies to Priority Health members and their providers.

    Policy Summary
    PayerPriority Health
    PolicyGenetics: Counseling, Testing, Screening
    Policy CodePolicy N/A
    Change TypeOperational additions (scope, FDA/regulatory, guideline, government references)
    Effective DateMar 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionObtain Evicore electronic prior authorization for tests annotated eC PA via Priority Health Prism.
    SourceLink
    POLICY UPDATE CHANGES

    New Policy Scope section added.

    New FDA/Regulatory section added.

    New Medical/Professional Society Guidelines section added.

    New Government Regulations section listing applicable CMS NCDs or LCDs.

    eC PASelected tests require PA
    CounselingPre- and post-test counseling required
    rWGS criteriarWGS pediatric inpatient limitation
    Not CoveredNot Covered examples
    ~200+Codes listed

    Coverage Criteria & Clinical Indications

    General medical necessity

    Covered when ALL of the following are met:

    Core medical necessity for testing: 1. Appropriate genetic counseling occurs before and after testing (genetic counseling must be by a board-certified genetic counselor independent of the testing laboratory where required); AND 2. Documented informed consent occurs before testing (follow Michigan law 333.17020); AND 3. Prior authorization is obtained where required (selected tests require prior authorization administered through Evicore).

    See Appendix A for conditions requiring counselor-delivered counseling; access Evicore via Priority Health Prism for authorization criteria.

    Rapid Whole Genome Sequencing

    Rapid whole genome sequencing (rWGS) is medically necessary when ALL of the following are met:

    rWGS criteria: 1. Ordered after determination by a Board-Certified or Board-Eligible Medical Geneticist that testing could be useful in establishing a diagnosis and treatment options; AND 2. Member is < 18 years of age; AND 3. Member is an acutely ill inpatient who is tested either (a) within 1 week of admission, OR (b) within 1 week of development of an abnormal response to standard therapy for an underlying condition.

    Priority Health requires notification of intent to perform inpatient rWGS via the Genetics medical policy prior notification form to avoid delays.

    Prenatal cfDNA screening (NIPT)

    Covered when ALL of the following are met:

    NIPT criteria: 1. Appropriate education and counseling occurs prior to testing; AND 2. Pregnancy is a singleton or twin gestation; AND 3. Gestational age is within the window validated by the selected testing laboratory.

    Cell-free DNA screening for sex chromosomes and less common trisomies are not separately payable; cfDNA screening for microdeletions and single-gene prenatal cfDNA screening is considered investigational.

    Exclusions / Not medically necessary

    The following are exclusions and considered not medically necessary unless otherwise authorized by individual case review:

    General exclusions: Routine, ongoing, or long-term genetic counseling; genetic testing to determine paternity; genetic testing to determine fetal sex; general population carrier screening (e.g., cystic fibrosis) when not meeting Evicore criteria; prenatal cfDNA screening for chromosome microdeletions or single-gene mutations (investigational); chemosensitivity assays (experimental/investigational); rWGS for inpatient members whose clinical course is fully explained by non-genetic causes (examples: infection/sepsis with normal response to therapy, isolated prematurity, isolated transient neonatal tachypnea, isolated unconjugated hyperbilirubinemia, hypoxic ischemic encephalopathy with clear precipitating event, meconium aspiration).

    List is not all-inclusive; individual case review may allow coverage for investigational yet promising care with prior plan approval.

    Testing of non-member relatives

    Testing of non-member relatives may be covered when ALL of the following are met:

    Non-member relative testing: 1. The non-member relative's test results are for the direct medical benefit of the Priority Health member and testing the non-member is the most cost‑effective method to obtain the information; AND 2. The non-member relative's insurer has been billed and payment denied; AND 3. Coverage is limited to testing up to five non‑member relatives lifetime per member; AND 4. Testing of the non‑member relative has been recommended by a genetics counselor and approved by Priority Health; AND 5. All testing must be processed through a Priority Health provider phlebotomist and laboratory unless otherwise specified by the genetics counselor.

    Testing that does not provide direct medical benefit to the member is not medically necessary unless criteria above are satisfied.

    Per-code coverage actions (eC PA / Review in panels / Not Covered)

    Per-code annotations in the coding lists indicate the payer action to apply for each listed code:

    Annotation types: Each CPT/PLA code entry includes one of the payer annotations: 'eC PA' (electronic clinical prior authorization required), 'Review in panels' (covered without single-code PA but reviewed within panel/clinical review processes), or 'Not Covered' for the specified plan; follow the annotation for that code when ordering or billing.

    See individual code entries in the Coding section for the specific annotation per code and per plan.

    Per-code coverage categorizations

    Coverage stance is assigned per code in the coding lists; apply the corresponding process below:

    Covered with prior authorization: Tests annotated 'eC PA' for a given plan (Commercial, Medicaid, Priority Medicare) are covered when electronic prior authorization is obtained through the payer's eC PA process.

    Providers must submit required documentation and follow Evicore/Prism authorization steps.

    Not Covered: Tests explicitly annotated 'Not Covered' in the per-code entries will be denied for coverage when billed to the specified plan.

    Examples of Not Covered codes are listed in the Coding module (see per-code entries).

    No PA / OOS: Some codes are designated OOS for electronic prior authorization or explicitly state 'No PA required' (for example: 81420 fetal aneuploidy cfDNA panel); even when No PA is indicated, documentation must support medical necessity.

    Verify per-code payer column before ordering.

    Not Covered

    The following tests and test categories are identified in the coding lists as Not Covered for the indicated plans:

    Not Covered tests (examples): Selected proprietary/PLA tests and multiple red blood cell antigen genotyping tests (examples in the coding list: numerous 0181U–0201U entries), certain microbial cfDNA assays (e.g., 0152U Karius), and other U-code entries are annotated 'Not Covered' for specified lines of business.

    Refer to the Coding module for the exact per‑code Not Covered designations by plan.

    Prior Authorization Required (eC PA)

    Tests labeled 'eC PA' require electronic prior authorization before testing may be billed for coverage:

    eC PA tests: Tests annotated 'eC PA' in the per-code lists require electronic clinical prior authorization via Evicore/Priority Health Prism prior to performance and billing.

    Providers must submit clinical rationale and supporting documentation per Evicore criteria; failure to obtain PA may result in denial.

    Priority Medicare — No PA required (OOS)

    For Priority Medicare-designated codes:

    OOS / No PA for Priority Medicare: Specific tests annotated 'OOS for eC - No PA required' under Priority Medicare do not require electronic prior authorization for that product as listed; coverage still depends on plan-specific terms.

    Examples include select Genomic Unity single‑gene tests annotated OOS for Priority Medicare in the coding lists.

    Coverage designations (per-code)

    Coverage designations are provided per U-code and per plan; apply the listed designation when ordering/billing:

    eC PA designation: Many U-codes and PLA/proprietary test codes in the lists are designated 'eC PA' for Commercial, Medicaid, and Priority Medicare and require prior authorization prior to coverage.

    See individual U-code entries for aliases and specific lab/test names.

    Not Covered designation: Specific U-codes are explicitly listed as 'Not Covered' for one or more plans (examples include 0425U/0426U/0429U/0463U/0490U–0492U); claims for these codes will be denied for the annotated plan(s).

    Confirm per-code plan column in the Coding section.

    Diagnosis-limited coverage: Some tests are covered only for specified diagnoses (example: 0471U covered only for listed ICD-10 codes); claims must include the indicated diagnosis code(s) for coverage consideration.

    Review per-code entry for exact diagnosis list requirements.

    Per-test coverage designations

    Per-test coverage varies by code and by plan; examples below summarize common stances:

    Tests Not Covered (per examples): Certain PLA/proprietary codes are listed as 'Not Covered' for one or more plans (examples in coding lists: 0491U, 0492U, 0500U, 0511U, 0512U, 0513U, 0532U).

    Refer to the Coding section for full per‑code plan mapping.

    Tests Covered with Prior Authorization: Many PLA codes are designated 'eC PA' indicating coverage is available when electronic clinical prior authorization is obtained (examples include 0493U, 0494U, 0495U, 0496U, 0497U and numerous others).

    Providers must follow Evicore/Prism authorization pathways and submit required documentation.

    General Coverage Stance

    General coverage and prior authorization stance for listed procedures:

    General coding coverage: Multiple cytogenetic and pathology CPT codes (listed) are designated OOS for eC (No PA required) for certain products; unlisted codes require explanatory notes to accompany claims. Many molecular and proprietary tests require eC PA or are Not Covered per the code-specific listing.

    Examples: chromosome analysis and FISH codes (88264, 88267, 88269, 88271–88273) are OOS for eC - No PA; unlisted codes (81479, 81599, 88399, 89240) require explanatory notes with claims.

    Exceptions and Prior Authorization

    Exceptions and cases requiring specific benefit riders or prior authorization:

    Fertility rider requirement: Codes 89290 and 89291 (preimplantation genetic biopsy) are covered only with the Fertility Rider for commercial plans; they are Not Covered for Medicaid and Priority Medicare.

    Claims for these codes require verification of fertility rider coverage.

    Prior authorization required: G9143 (warfarin responsiveness genetic testing) and numerous listed genetic tests require electronic prior authorization as annotated; obtain PA per Evicore/Prism instructions.

    Failure to obtain PA where indicated may result in denial.

    Genetic counseling and testing are covered only when they meet medical necessity criteria and documentation requirements. Routine, ongoing, or long‑term genetic counseling and testing performed solely for paternity determination or to determine fetal sex are excluded. Prenatal cell‑free DNA screening limited to common fetal aneuploidies (trisomy 21, 13, 18) is covered when pre‑test education and counseling occur and the pregnancy and gestational age meet lab validation; by contrast, prenatal cfDNA screening for chromosome microdeletions and for single‑gene mutations is investigational and not payable. Testing of non‑member relatives may be considered only when the non‑member’s insurer has been billed and denied, testing provides direct medical benefit to the member, testing is the most cost‑effective option, testing is limited to up to five non‑member relatives in a member’s lifetime, and testing is recommended by a genetics counselor and approved by Priority Health. All genetic testing must be processed per the policy (Priority Health provider phlebotomist and laboratory) unless otherwise specified.

    Certain emerging or menu‑based assays are explicitly considered investigational or not medically necessary. Chemosensitivity assays (live tumor cell culture drug‑response testing) are categorized as experimental/investigational and are not medically necessary. Prenatal cfDNA uses beyond standard aneuploidy screening (for example, microdeletions or single‑gene prenatal cfDNA) are also considered investigational. Providers seeking coverage for investigational testing may request individual case review, but such requests require prior plan approval and review by a Priority Health medical director or clinical pharmacist.

    Covered Indications & Use Cases

    CPT/PLA/U-code Listings & Code Tables

    Genetic counseling and selected genetic test CPT codes (examples)CPT
    96041Medical genetics and genetic counseling services, each 30 minutes of total time provided by the genetic counselor on the date of the encounter
    S0265Genetic counseling, under physician supervision, each 15 minutes
    81105Human Platelet Antigen 1 genotyping (HPA-1), ITGB3, gene analysis, common variant, HPA-1a/b
    81106Human Platelet Antigen 2 genotyping (HPA-2), GP1BA, gene analysis, common variant, HPA-2a/b
    81107Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B, gene analysis, common variant, HPA-3a/b
    Listed CPT codes and descriptionsCPT
    81105Human Platelet Antigen 1 genotyping (HPA-1)
    81106Human Platelet Antigen 2 genotyping (HPA-2)
    81107Human Platelet Antigen 3 genotyping (HPA-3)
    81108Human Platelet Antigen 4 genotyping (HPA-4)
    81109Human Platelet Antigen 5 genotyping (HPA-5)
    81110Human Platelet Antigen 6 genotyping (HPA-6w)
    81111Human Platelet Antigen 9 genotyping (HPA-9w)
    81112Human Platelet Antigen 15 genotyping (HPA-15)
    81120IDH1 common variants
    81121IDH2 common variants
    1–10 of 71
    1/8
    Mixed gene tests (excerpt start)CPT
    81225CYP2C19 gene analysis, common variants (eg, *2, *3, *4, *8, *17)
    81226CYP2D6 gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)
    81227CYP2C9 gene analysis, common variants (eg, *2, *3, *5, *6)
    81228Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; CGH microarray analysis
    81229Cytogenomic analysis for copy number and SNP variants; CGH microarray analysis
    Gene sequencing and variant analysisCPT
    81230CYP3A4 gene analysis, common variant(s) (eg, *2, *22)
    81231CYP3A5 gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)
    81232DPYD gene analysis, common variant(s) (eg, *2A, *4, *5, *6)
    81233BTK gene analysis, common variants (eg, C481S, C481R)
    81234DMPK gene analysis; evaluation to detect expanded alleles (myotonic dystrophy type 1)
    81235EGFR gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A/S, L861Q)
    81236EZH2 gene analysis, full gene sequence
    81237EZH2 gene analysis, common variant(s) (eg, codon 646)
    81238F9 full gene sequence (hemophilia B)
    81239DMPK characterization of alleles (expanded size)
    Hereditary & somatic variant testsCPT
    81240F2 prothrombin 20210G>A variant analysis
    81241F5 Factor V Leiden variant analysis
    81242FANCC gene analysis, common variant (eg, IVS4+4A>T)
    81243FMR1 evaluation to detect expanded alleles (Fragile X)
    81244FMR1 characterization of alleles (expanded size and promoter methylation)
    81245FLT3 internal tandem duplication (ITD) variants analysis (exons 14,15)
    81246FLT3 tyrosine kinase domain (TKD) variants analysis (eg, D835, I836)
    Metabolic and hearing loss genesCPT
    81247G6PD gene analysis; common variant(s) (eg, A, A-)
    81248G6PD known familial variant(s)
    81249G6PD full gene sequence
    81250G6PC gene analysis, common variants (eg, R83C, Q347X)
    81251GBA gene analysis, common variants (eg, N370S, 84GG, L444P)
    81252GJB2 full gene sequence (nonsyndromic hearing loss)
    81253GJB2 known familial variants
    Additional hereditary and hematologic testsCPT
    81254GJB6 common deletion variants (eg, del(GJB6-D13S1830), del(GJB6-D13S1854))
    81255HEXA gene analysis, common variants (eg, 1278insTATC, 1421+1G>C, G269S)
    81256HFE gene analysis, common variants (eg, C282Y, H63D)
    81257HBA1/HBA2 gene analysis for common deletions/variants (alpha thalassemia)
    81258HBA1/HBA2 known familial variant
    81259HBA1/HBA2 full gene sequence
    81260IKBKAP gene analysis, common variants (eg, 2507+6T>C, R696P)
    81261IGH@ gene rearrangement analysis; amplified methodology
    Remaining gene and cytogenomic tests in excerptCPT
    81262IGH@ gene rearrangement analysis; direct probe methodology
    81263IGH@ variable region somatic mutation analysis
    81264IGK@ gene rearrangement analysis
    81265Comparative STR analysis (patient and comparative specimen)
    81266Comparative STR analysis; each additional specimen
    81267Chimerism (engraftment) analysis, without cell selection
    81268Chimerism analysis, with cell selection, each cell type
    81269HBA1/HBA2 duplication/deletion variants
    81270JAK2 p.Val617Phe (V617F) variant analysis
    81271HTT evaluation to detect expanded alleles (Huntington disease)
    1–10 of 32
    1/4
    Listed CPT Codes (81291–81360)CPT
    81291CODE ENTRY (listed in segment)
    81292MLH1 gene analysis; full sequence analysis
    81293MLH1 gene analysis; known familial variants
    81294MLH1 gene analysis; duplication/deletion variants
    81295MSH2 gene analysis; full sequence analysis
    81296MSH2 gene analysis; known familial variants
    81297MSH2 gene analysis; duplication/deletion variants
    81298MSH6 gene analysis; full sequence analysis
    81299MSH6 gene analysis; known familial variants
    81300MSH6 gene analysis; duplication/deletion variants
    1–10 of 67
    1/7
    Explicitly Not Covered (per lines of business)CPTNot Covered
    81324PMP22 (duplication/deletion) - MEDICAID: Not Covered; PRIORITY MEDICARE: Not Covered
    81330SMPD1 - PRIORITY MEDICARE: Not Covered
    81331SNRPN/UBE3A methylation - PRIORITY MEDICARE: Not Covered
    81334RUNX1 - MEDICAID: Not Covered
    Codes 'Review in panels'CPT
    81301Microsatellite instability analysis - Review in panels
    81305MYD88 L265P - Review in panels
    81309PIK3CA - Review in panels
    Listed CPT/PLA Codes and DescriptionsCPT
    81351TP53 full gene sequence
    81352TP53 targeted sequence analysis
    81353TP53 known familial variant
    81354Cytogenomic (genome-wide) analysis; OGM
    81355VKORC1 common variant(s)
    81357U2AF1 common variants
    81360ZRSR2 common variants
    81361HBB common variants (eg HbS, HbC)
    81362HBB known familial variant(s)
    81363HBB duplication/deletion variants
    1–10 of 65
    1/7
    Covered CPT Codes group (examples)CPT
    81552Oncology (uveal melanoma), mRNA gene expression profiling of 15 genes; risk of metastasis.
    81554Pulmonary disease (IPF), mRNA gene expression of 190 genes; diagnostic algorithm (probability of UIP).
    81558Transplantation medicine (kidney allograft rejection), mRNA profiling of 139 genes from whole blood; binary outcome for transplant excellence or not.
    81595Cardiology (heart transplant), mRNA gene expression profiling of 20 genes; rejection risk score. Alias: AlloMap®.
    81596Infectious disease (chronic HCV), six biochemical assays; prognostic scores for fibrosis and necroinflammatory activity. Alias: Fibrotest/Fibrosure.
    81599Unlisted multianalyte assay with algorithmic analysis; explanatory notes identifying specific test must accompany claim.
    84999Unlisted chemistry procedure; explanatory notes identifying specific test must accompany claim.
    Listed Test Codes and Descriptionsmixed
    0002MLiver disease, ten biochemical assays; prognostic algorithm (NASH FibroSURE)
    0003MLiver disease, ten biochemical assays; prognostic algorithm (NASH FibroSURE)
    0004MScoliosis, DNA analysis of 53 SNPs; prognostic risk score (ScoliScore)
    0006MOncology (hepatic), mRNA expression of 161 genes with AFP; risk classifier (HeproDX)
    0007MOncology (GI NET), PCR expression analysis of 51 genes; tumor disease index (NETest)
    0011MOncology (prostate), mRNA assay of 12 genes in plasma/urine; predicts high-grade prostate cancer risk
    0012MOncology (urothelial), mRNA profiling of five genes in urine; risk score for urothelial carcinoma (CxBladder)
    0013MOncology (urothelial), mRNA profiling for recurrence (CxBladder Monitor)
    0016MOncology (bladder), mRNA microarray profiling of 219 genes; molecular subtype classification (Decipher Bladder)
    0017MOncology (DLBCL), mRNA expression profiling of 20 genes; cell of origin (Lymph2Cx)
    1–10 of 21
    1/3
    Explicitly Not Covered Codes (per payer columns)mixedNot Covered
    0005UCOMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered.
    0010UCOMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered.
    0040UCOMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered.
    0046UCOMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered.
    0049UCOMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered.
    0055UCOMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered.
    Listed U-codes and descriptionsCPT
    0073Ulisted; coverage = eC PA (MEDICAID = eC PA, PRIORITY MEDICARE = eC PA)
    0074UCYP2D6 targeted sequence analysis (non-duplicated gene when duplication/multiplication is trans); COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0075UCYP2D6 5' gene duplication/multiplication targeted sequence analysis; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0076UCYP2D6 3' gene duplication/multiplication targeted sequence analysis; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0078UPain management genotyping panel, 16 variants; COMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered
    0084URed blood cell antigen typing, DNA, genotyping of 10 blood groups; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0086UInfectious disease organism identification, blood culture rRNA FISH, 6+ targets; COMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered
    0087UCardiology (heart transplant) mRNA gene expression profiling of 1283 genes; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0088UKidney allograft rejection microarray profiling of 1494 genes; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0089UOncology (melanoma) gene expression profiling via adhesive patch; COMMERCIAL PLANS = OOS for eC - No PA required; MEDICAID = Not Covered; PRIORITY MEDICARE = OOS for eC - No PA required
    1–10 of 19
    1/2
    Not Covered (selected PLA codes)mixedNot Covered
    0181UNavigator CO Sequencing / Grifols Immunohematology Center — COMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered
    0182URed cell antigen (Cromer) genotyping CD55 exons 1-10; Not Covered
    0183URed cell antigen (Diego) genotyping SLC4A1 exon 19; Not Covered
    0184URed cell antigen (Dombrock) genotyping ART4 exon 2; Not Covered
    0185URed cell antigen (H) genotyping FUT1 exon 4; Not Covered
    0186URed cell antigen (H) genotyping FUT2 exon 2; Not Covered
    0187URed cell antigen (Duffy) genotyping ACKR1 exons 1-2; Not Covered
    0189URed cell antigen (MNS) genotyping GYPA introns/exon 2; Not Covered
    0190URed cell antigen (MNS) genotyping GYPB introns/pseudoexon 3; Not Covered
    0191URed cell antigen (Indian) genotyping CD44 exons 2,3,6; Not Covered
    1–10 of 19
    1/2
    Mixed: eC PA or Not Covered or OOS entriesmixed
    0203UPredictSURE IBD Test (mRNA, IBD aggressiveness, 17 genes) — COMMERCIAL PLANS = eC PA
    0205UVita Risk (AMD test, 3 gene variants) — COMMERCIAL PLANS = eC PA
    0209UCNGnome (melanoma mRNA profiling, 23 genes) — COMMERCIAL PLANS = eC PA
    0211UMI Cancer Seek NGS Analysis (pan-tumor DNA/RNA NGS) — COMMERCIAL PLANS = eC PA
    0212UGenomic Unity Exome Plus Analysis - Proband (whole genome & mitochondrial) — Not Covered
    0213UGenomic Unity Whole Genome Analysis - Comparator — Not Covered
    0214UGenomic Unity Exome Plus Analysis - Proband (alternate listing) — eC PA
    0215UGenomic Unity Exome Plus Analysis - Comparator — eC PA
    0216UGenomic Unity Ataxia Repeat Expansion and Sequence Analysis (12 genes) — eC PA
    0217UGenomic Unity Comprehensive Ataxia Repeat Expansion and Sequence Analysis (51 genes) — eC PA
    1–10 of 36
    1/4
    Listed Proprietary/PLA CPT CodesCPT
    0260UOptical genome mapping for rare/constitutional/heritable disorders
    0262UOncology (solid tumor), gene expression profiling by RT‑PCR of 7 gene pathways
    0264UOptical genome mapping for rare/constitutional/heritable disorders
    0265UWhole genome and mitochondrial DNA sequence analysis for rare constitutional/heritable disorders
    0266UWhole-transcriptome tissue-specific gene expression for unexplained constitutional/heritable disorders
    0267UOptical genome mapping and whole genome sequencing for rare constitutional disorders
    0268UGenomic sequence analysis of 15 genes for atypical hemolytic uremic syndrome (aHUS)
    0269UGenomic sequence analysis of 14 genes for autosomal dominant congenital thrombocytopenia
    0270UGenomic sequence analysis of 20 genes for congenital coagulation disorders
    0271UGenomic sequence analysis of 23 genes for congenital neutropenia
    1–10 of 38
    1/4
    Listed U-code Tests and Coverage Stancemixed
    0328UAlias/Test Name examples listed; COMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered
    0329UOncology exome and transcriptome sequence analysis with tumor and normal subtraction; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0330UInfectious agent detection vaginal pathogen panel (27 organisms); COMMERCIAL PLANS = Not Covered; MEDICAID = Not Covered; PRIORITY MEDICARE = Not Covered
    0331UOptical genome mapping for hematolymphoid neoplasia; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0332UEpigenetic 8-marker qPCR predicting checkpoint-inhibitor response; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0333UHCC surveillance cfDNA methylation + AFP/AFP-L3/DCP algorithm; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0334UTargeted tumor sequencing (>=84 genes) FFPE; COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0335UWhole genome sequence analysis for rare/heritable disorders (proband); COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0336UWhole genome sequence analysis comparator (eg parent); COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    0339UProstate mRNA HOXC6/DLX1 expression test (SelectMDx); COMMERCIAL PLANS = eC PA; MEDICAID = eC PA; PRIORITY MEDICARE = eC PA
    1–10 of 20
    1/2
    Listed CPT/Proprietary U-codes (additional group)mixed
    0433UOncology (prostate), 5 DNA regulatory markers by qPCR, whole blood (EpiSwitch® Prostate Screening Test)
    0434UDrug metabolism genomic panel, 25 genes (RightMed® Gene Test)
    0437UPsychiatry (anxiety), mRNA expression profiling of 15 biomarkers, whole blood
    0438UDrug metabolism buccal specimen panel, 33 genes including CYP2D6 del/dup
    0439UCardiology (CHD), DNA SNPs and methylation markers qPCR/digital PCR, algorithmic risk
    0444UOncology (solid organ), targeted genomic sequencing panel of 361 genes from FFPE
    0449UCarrier screening panel including CFTR, SMN1, HBB, HBA1, HBA2
    Listed CPT/Proprietary U-codes (oncology/rare disease)mixed
    0452UOncology (bladder), methylated PENK DNA detection by LTE-aMSP, urine
    0453UOncology (colorectal cancer), cfDNA methylation-based qPCR assay (SEPTIN9, IKZF1, BCAT1, others)
    0454URare disease optical genome mapping for CNVs, inversions, translocations
    0460UOncology, DNA SNP genotyping by real-time PCR of 24 genes, reported phenotypes (RightMed® Oncology Gene Report)
    0461UOncology pharmacogenomic analysis of 24 genes by real-time PCR
    0463UOncology (cervix), mRNA profiling of 14 biomarkers (Proofer '7 HPV mRNA E6/E7) — Not Covered
    Listed CPT/Proprietary U-codes (germline, pharmacogenomics, tumor)mixed
    0471UOncology (colorectal cancer), qualitative real-time PCR of 35 KRAS/NRAS variants; coverage limited to specified ICD-10 diagnoses
    0473UOncology (solid tumor), NGS of FFPE tissue with matched normal, 648 genes
    0474UHereditary pan-cancer germline panel, 88 genes
    0475UHereditary prostate cancer panel, 23 genes plus del/dup when indicated
    0476UDrug metabolism psychiatry, genotyping of 14 genes plus CYP2D6 CNV (RightMed® MentalHealth)
    0477UDrug metabolism psychiatry, 14 genes plus CYP2D6 CNV with gene-drug interactions
    0478UOncology (NSCLC), DNA/RNA digital PCR analysis of 9 genes for actionable variants
    Listed CPT/Proprietary U-codes (additional assorted tests)mixed
    0481UIDH1, IDH2, and TERT promoter mutation analysis by NGS (CNS tumors)
    0485UOncology (solid tumor), cfDNA and RNA NGS with interpretive report for germline, CHIP, and tumor-derived variants (Caris Assure)
    0486UOncology (pan-solid tumor), NGS methylation analysis of cfDNA (Northstar Response)
    0487UOncology (solid tumor), cfDNA targeted NGS panel of 84 genes (Northstar Select)
    0488UObstetrics NIPT for fetal antigen(s) (Rh, Kell, Duffy) using cfDNA (UNITY Fetal Antigen)
    0489UObstetrics single-gene NIPT for paternal variants and maternal mutation dosage (UNITY Fetal Risk)
    0490UOncology (melanoma), circulating melanoma cell enumeration (CELLSEARCH® CMC) — Not Covered
    0491UOncology (solid tumor), circulating tumor cell enumeration with ER quantification (CELLSEARCH® ER) — Not Covered
    0492UOncology (solid tumor), circulating tumor cell enumeration with PD-L1 quantification (CELLSEARCH® PDL1) — Not Covered
    0493UTransplantation medicine, donor-derived cfDNA quantification (Prospera™)
    1–10 of 14
    1/2
    Listed PLA/Proprietary Test Codesmixed
    0491UCELLSEARCH® PDL1 Circulating Tumor Cell Test (EpCAM, cytokeratins, CD45, PD-L1), peripheral blood
    0492UCELLSEARCH® PDL1 Circulating Tumor Cell Test (alias listed)
    0493UDonor-derived cell-free DNA quantification (Prospera™)
    0494UFetal RhD gene analysis from maternal cfDNA (Rh Test, Natera)
    0495UProstate panel (plasma proteins + polygenic risk score) (Stockholm3)
    0496UColorectal ctDNA: mutations, methylation, proteins (ColoScape™ PLUS)
    0497UProstate mRNA expression profiling (OncoAssure™ Prostate)
    0498UColorectal NGS and methylation panel (OptiSeq™ Colorectal Cancer NGS Panel)
    0499UColorectal and lung 8-gene NGS panel (OptiSeq™ Dual Cancer Panel Kit)
    0500UUBA1 targeted variant analysis for VEXAS syndrome (QClamp® Plex VEXAS)
    1–10 of 48
    1/5
    CPT and other codes with plan designationsmixed
    82172Apolipoprotein, each — OOS for eC - No PA required
    83006Growth stimulation expressed gene 2 (ST2) — OOS for eC - Not Covered
    83950Oncoprotein; HER-2/neu — OOS for eC - No PA required
    83951Oncoprotein; des-gamma-carboxy-prothrombin (DCP) — OOS for eC - Not Covered
    83993Calprotectin, fecal — OOS for eC- No PA required
    84233Receptor assay; estrogen — OOS for eC- No PA required
    84234Receptor assay; progesterone — OOS for eC- No PA required
    86152Cell enumeration (eg circulating tumor cells) — OOS for eC - Not Covered
    86153Cell enumeration w/ physician interpretation — OOS for eC - Not Covered
    86294Immunoassay for tumor antigen, qualitative (eg, BTA Stat) — OOS for eC- No PA required; covered only for specified bladder diagnoses
    1–10 of 32
    1/4
    Listed CPT/HCPCS codes in this document excerptmixed
    88264Chromosome analysis (mentioned as required).
    88267Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, 1 karyotype, with banding.
    88269Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding.
    88271Molecular cytogenetics; DNA probe, each (eg, FISH).
    88272Molecular cytogenetics; chromosomal in situ hybridization, analyze 3-5 cells (eg, for derivatives and markers).
    88273Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions).
    88274Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells.
    88275Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells.
    88280Chromosome analysis; additional karyotypes, each study.
    88283Chromosome analysis; additional specialized banding technique (eg, NOR, C-banding).
    1–10 of 33
    1/4

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Obtain Evicore prior authorization for selected tests

    Prior authorization for selected genetic tests and many procedure codes must be obtained through Evicore via Priority Health Prism; the policy states selected tests require prior authorization administered through Evicore and directs providers to Log into Priority Health Prism → Authorizations → Authorization Criteria Lookup to access Evicore guidelines.

    • Applies notably to procedure codes in the 81105–81599 range and many listed CPT/PLA codes.
    • Initiate the Evicore request using the procedure code that requires PA via the provider portal.
    Prior Authorization

    Submit eC PA for specified hereditary and key gene tests

    Many hereditary and clinically significant gene tests are designated 'eC PA' and require electronic prior authorization for Commercial, Medicaid, and Priority Medicare lines; providers must submit PA per the payer's electronic workflow.

    • Examples include BRCA1/BRCA2 (81162–81165) and multiple pharmacogenomic genes (81225–81227).

    Not Covered / Exclusions

    The policy lists a number of specific tests and test categories that are Not Covered. Examples include prenatal cfDNA screening for microdeletions and single‑gene mutations (investigational), chemosensitivity assays (experimental/investigational), and multiple proprietary or PLA tests identified in the coding tables as 'Not Covered' for the indicated plan(s). Tests annotated as 'Not Covered' in the code listings will be denied when billed under the plan(s) indicated unless an exception is granted through individual case review and prior plan approval.

    Several proprietary U‑code examples are listed as Not Covered across Commercial, Medicaid, and Priority Medicare columns. Examples include 0005U, 0010U, 0040U, 0046U, 0049U, and 0055U — each shown in the coding table with a 'Not Covered' designation for the specified benefit lines.

    Priority Medicare examples in the coding tables show specific CPT entries annotated 'Not Covered.' For instance, CPT codes 81240–81243 (F2, F5, FANCC, FMR1 related entries) include 'PRIORITY MEDICARE = Not Covered' annotations in the coding section; providers should follow the plan‑specific column when submitting claims.

    Some single‑gene CPT codes are explicitly listed as Not Covered for certain lines of business. For example, 81324 (PMP22 duplication/deletion analysis) is annotated as 'Not Covered' for MEDICAID and PRIORITY MEDICARE in the coding tables; check the payer‑column for plan‑specific noncoverage before ordering or billing.

    The policy explicitly lists specific multianalyte assays as Not Covered. One example is 81506 (PreDx Diabetes Risk Score), which is shown as not covered across Commercial, Medicaid, and Priority Medicare columns in the coding section.

    Many PLA/U‑code tests are explicitly listed as Not Covered in the payer columns. Examples called out in the code tables include 0005U, 0010U, 0040U, 0046U, 0049U, 0055U; verify the specific payer column for each U‑code prior to ordering or billing.

    Eligibility Requirements & Member Applicability

    Testing is indicated when there is increased risk based on documented family history, carrier status, or clinical findings consistent with a genetic disorder. For prenatal diagnostic testing, examples of indications include abnormal fetal ultrasound findings, abnormal maternal serum screening, or an increased risk based on family history or known carrier status. Pre‑ and post‑test genetic counseling and documentation of informed consent are required for medically necessary prenatal diagnostic testing.

    Eligibility for coverage follows the policy’s medical necessity criteria: testing must provide direct medical benefit to the member, be ordered with appropriate clinical justification and counseling, and comply with plan and Evicore authorization requirements where applicable. Selected tests require prior authorization through Evicore; follow the Evicore criteria accessible via Priority Health Prism for required clinical information, documentation, and authorization workflow.

    For testing of non‑member relatives, the policy requires that the non‑member relative’s insurer be billed and payment denied before Priority Health will consider covering testing of that relative. This step is an explicit precondition to coverage for non‑member relative testing.

    Coverage of familial testing is limited: Priority Health limits coverage to testing of up to five non‑member relatives per member over the member’s lifetime, and testing must be recommended by a genetics counselor and approved by Priority Health before proceeding.

    Eligibility determinations rely on appropriate documentation of counseling, indication, and prior authorization when required. Providers must document that testing will inform clinical management or provide a direct benefit to the member; otherwise testing may be considered not medically necessary.

    Definitions & Background

    Genetic counseling is an integral part of the testing process. Genetic counseling interprets family and medical history, educates individuals about inheritance, testing options, benefits, limitations, and potential psychosocial implications, and supports informed decision‑making. The policy requires documentation of pre‑ and post‑test counseling and informed consent in accordance with Michigan law and professional guidelines; for certain indications, counseling must be performed by a board‑certified genetic counselor independent of the testing laboratory.

    Definition — Genetic counseling
    DefinitionGenetic counseling: process to help individuals understand and adapt to medical, psychological and familial implications of genetic contributions to disease, including interpretation of family/medical history, education about inheritance/testing/management, informed decision support, and psychosocial/ethical discussion.
    Provider qualificationsGenetic counselors are defined as ABMG- or ABGC-certified physicians or master/doctorate-level genetics professionals with formal training in genetics and counseling.
    Scope of counselingIncludes pre-test and post-test counseling addressing inheritance, testing options, management, prevention, resources, research, autonomy, privacy, equity and confidentiality.

    Coding Notes, Thresholds & Key Values

    Age threshold for rWGS (member < 18 years)
    Age thresholdrWGS (rapid whole genome sequencing) is medically necessary only when the member is younger than 18 years of age (Member < 18 years).
    Ordering requirementrWGS must be ordered after determination by a Board-Certified or Board-Eligible Medical Geneticist that testing could aid diagnosis/treatment.
    Clinical timingAcutely ill inpatient member must be tested within 1 week of admission or within 1 week of an abnormal response to standard therapy.
    Specific variant examples — variant/exon examples for certain genes
    Variant examplesPolicy lists specific variant and exon examples for some genes (eg, KIT exons 8,11,13,17,18; FLT3 ITD exons 14,15; JAK2 V617F) used to define targeted testing scope.
    Panel detail

    Background & Context

    This policy applies to genetic counseling and genetic testing services described in the coding and coverage sections. Genetic counseling is required as part of medical necessity for many tests, and testing is intended to diagnose, guide management, or inform reproductive decisions. The policy summarizes the scope and limitations: routine counseling and tests for non‑medical purposes are excluded; specific tests require prior authorization or are designated not covered per plan‑level coding tables.

    Revision History & Policy Changes

    2026-03-01Operational additionsLatest

    Added Policy Scope, FDA/Regulatory, Medical/Professional Society Guidelines, and Government Regulations (CMS NCDs/LCDs) sections to the document header/operational content.

    Policy Summary
    PayerPriority Health
    PolicyGenetics: Counseling, Testing, Screening
    Policy CodePolicy N/A
    Change TypeOperational additions (scope, FDA/regulatory, guideline, government references)
    Effective DateMar 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionObtain Evicore electronic prior authorization for tests annotated eC PA via Priority Health Prism.
    SourceLink
    On This Page
    Coverage Criteria & Clinical IndicationsCovered Indications & Use CasesCPT/PLA/U-code Listings & Code TablesProvider Actions, Prior Authorization & DocumentationNot Covered / ExclusionsEligibility Requirements & Member ApplicabilityDefinitions & BackgroundCoding Notes, Thresholds & Key ValuesBackground & ContextRevision History & Policy Changes
  1. Follow the eC PA process shown in per-code entries when billing.
  2. Note

    Expect panel-level review for 'Review in panels' codes

    Some codes are designated 'Review in panels'—these codes are reviewed as part of a panel; they may be covered without PA when reported alone but will be subject to panel review or PA if reported with codes that require authorization.

    • Examples: multiple HLA, tumor, and single-gene entries noted as 'Review in panels'.
    • If included in a multi-code panel where any code requires PA, the procedure code that requires PA should trigger Evicore access.
    Prior Authorization

    Follow annotated PA or panel review processes

    Where a code is annotated as 'eC PA' or 'Review in panels' the provider must follow the payer's electronic clinical prior authorization or panel review process before testing or billing.

    • Use the procedure code requiring PA to initiate Evicore via the provider portal.
    • If codes are reported together, obtain PA for the code that requires authorization to avoid panel combination denial risk.
    Prior Authorization

    Obtain electronic prior authorization for eC PA codes

    Numerous CPT codes in the molecular/genetics sections are marked 'eC PA'—electronic prior authorization is required for coverage determination and must be obtained prior to testing.

    • Examples include 81292, 81295 and many panel/exome/genome codes (81415/81425, 81443, 81448).
    • Obtain PA through the payer's eC workflow before performing or billing these tests.
    Note

    Anticipate panel review for listed CPT codes

    Several CPT codes are marked 'Review in panels'; coverage decisions for these codes are made within panel-level review rather than as individually pre-approved tests—providers should expect clinical review and supply requested documentation.

    • Examples include microsatellite instability and selected tumor variant codes (81301, 81305, 81309).
    • Provide clinical justification and panel-level information when requested during review.
    Prior Authorization

    Obtain electronic clinical prior authorization for eC PA codes

    Codes annotated 'eC PA' require electronic clinical prior authorization for Commercial, Medicaid, and Priority Medicare plans; obtain the eC PA before testing to avoid coverage delays or denials.

    • Examples include many panel codes (81443, 81445, 81448–81451) and exome/genome codes (81415/81425).
    • Follow Evicore/Prism instructions to submit required clinical information.
    Note

    No PA required for 81420 (NIPT), but document counseling and indications

    Code 81420 (fetal chromosomal aneuploidy cfDNA panel for chromosomes 13, 18, 21) is designated 'No PA required'; however, documentation must still support medical necessity and pre-test counseling per policy.

    • Provide documentation of appropriate education and counseling prior to testing.
    • Ensure gestational age and pregnancy type (singleton/twin) meet laboratory-validated criteria.
    Prior Authorization

    Obtain eC PA for many listed CPT/PLA codes

    Many CPT and PLA U-codes in the lists are annotated 'eC PA' indicating electronic case review/prior authorization is required for Commercial, Medicaid, and Priority Medicare plans; obtain prior authorization through the eC process for those codes.

    • Examples include numerous panel and proprietary tests (81552, 81554, 81558, 0003U, many U-codes).
    • Do not submit claims for these tests without first securing required eC PA.
    Note

    Verify per-code 'No PA Required' exceptions before ordering

    Certain tests are explicitly listed as 'No PA Required' (OOS or No PA) — examples include some fetal aneuploidy cfDNA entries and screening tests such as Cologuard; verify per-code payer columns before ordering.

    • 81507/81528 and select NIPT entries are noted as 'No PA Required' or OOS for eC.
    • Confirm the per-code column (Commercial/Medicaid/Priority Medicare) for plan-specific PA requirements.
    Prior Authorization

    Obtain eC PA for listed proprietary and panel tests

    The per-code listings identify many tests that require electronic prior authorization ('eC PA'); when a test is listed as eC PA providers must obtain authorization through the electronic claims/prior authorization process before testing or billing.

    • Examples span proprietary U-codes and multi-gene panels where eC PA is the listed coverage action.
    • Follow Evicore via Priority Health Prism for submission and required documentation.
    Note

    0003U is OOS for commercial plans (no PA) — verify payer column for coverage

    Code 0003U (Overa/OVA1 Next Generation) is listed as OOS for commercial plans and requires no PA for in-network providers; Medicaid is listed as Not Covered for this test.

    • Confirm plan-specific status before ordering; OOS indicates out-of-scope for Evicore management and No PA required for in-network providers.
    • If member has Medicaid, the code is Not Covered per the listing.
    Note

    Check per-code coverage/PA notes (No PA required vs Not Covered)

    Per-code payer columns show some codes explicitly labeled 'No PA required' or 'Not Covered' depending on the plan; providers must verify the code-specific payer column (Commercial/Medicaid/Priority Medicare) prior to ordering and billing.

    • Examples: 0027U may be No PA required for certain plans; 0040U/0046U/0049U are listed Not Covered in specified columns.
    • Use the code-specific annotation to determine whether to request PA or expect denial.
    Prior Authorization

    Obtain eC PA via electronic claims/prior authorization for eC PA codes

    Codes listed as 'eC PA' require prior authorization through the payer's electronic prior authorization process; obtain the eC PA before performing or billing the test to meet coverage requirements.

    • This applies to many U-code proprietary tests and newer PLA entries designated eC PA.
    • Submit required clinical rationale and supporting documentation in the eC PA request.
    Prior Authorization

    eC PA required before billing for 'eC PA' tests

    Tests identified as 'eC PA' in code entries must have electronic prior authorization per the plan designation; providers should not proceed without completing the eC PA workflow for those codes.

    • This is reiterated across many code groups—eC PA is the expected authorization pathway for panels, cfDNA, and specialty tests.
    • Follow Evicore/Prism instructions to submit complete clinical information.
    Prior Authorization

    Obtain PA for many proprietary molecular/genetic tests

    Numerous proprietary molecular/genetic tests (U-codes and PLA codes) are designated 'eC PA' across Commercial, Medicaid, and Priority Medicare — obtain prior authorization per the payer policy for these tests before testing.

    • Examples include optical genome mapping (0260U), whole genome sequencing (0265U), and many tumor/ctDNA panels.
    • Failure to obtain required PA may lead to denial or medical necessity review.
    Prior Authorization

    Obtain eC PA for U-code proprietary tests before billing

    Many U-codes in the U-code listings are labeled 'eC PA' indicating electronic claim prior authorization is required for coverage; obtain prior authorization through Evicore/Priority Health Prism when billing these U-codes.

    • Examples: 0326U (Guardant360), 0334U, 0340U (Signatera) and numerous cfDNA/oncology U-codes.
    • Submit specimen type, prior tumor/germline sequencing when requested, and clinical rationale with the PA.
    Prior Authorization

    Obtain evidence-based clinical prior authorization for many tests

    Many listed tests across sections are labeled 'eC PA' for Commercial, Medicaid, and Priority Medicare; providers must obtain evidence-based clinical prior authorization per the payer policy before testing.

    • This includes transplant, oncology, reproductive, and specialty genomic assays (eg, 0422U, 0473U, 0485U).
    • Follow Evicore guidance and include required clinical details for the review.
    Prior Authorization

    Secure eC PA for PLA/U-code tests per plan annotations

    Tests marked 'eC PA' in the PLA/test code listings require electronic clinical prior authorization before they will be covered for the specified plan(s); secure the eC PA via the payer's system.

    • Examples include many PLA codes in the 0490–0578U range and beyond.
    • Include diagnosis, prior testing, specimen type, and test description in the PA submission as indicated.
    Prior Authorization

    Obtain eC PA for listed U-codes via Evicore

    Multiple U-codes in the later U-code lists are designated 'eC PA' for commercial, Medicaid, and Priority Medicare; providers must obtain electronic prior authorization for these U-codes prior to testing or billing.

    • Examples include 0572U, 0575U, 0582U, 0585U, 0592U.
    • Follow Evicore/Priority Health Prism to submit PA and required documentation.
    Prior Authorization

    Follow Priority Health/ Evicore PA and benefit-rider rules

    Certain genetic tests require prior authorization via Priority Health systems or are covered only with specific benefit riders; providers should follow Evicore guidelines via Priority Health Prism and submit requests demonstrating medical necessity.

    • Examples: G9143 (warfarin pharmacogenetic testing) requires eC PA; preimplantation genetic biopsy codes 89290/89291 are covered only with a Fertility Rider.
    • When tests are covered only with a rider, verify member benefits before ordering.
    Documentation Required

    Document genetic counseling and informed consent

    Document that pre- and post-test genetic counseling occurred and retain informed consent records; Michigan law (Public Health Code Act 368 of 1978: 333.17020) requires informed consent for genetic testing.

    • Genetic counseling must be by a board‑certified genetic counselor independent of the testing laboratory for specified conditions.
    • Document counseling and informed consent in the medical record prior to testing.
    Billing Rule

    Initiate PA using the procedure code that requires authorization

    Initiate Evicore prior authorization using the procedure code that requires PA; the policy specifies the procedure requiring PA should initiate access to Evicore via the provider portal.

    • If multiple codes are reported, use the procedure code that requires PA to start the Evicore request.
    • Access Evicore via Priority Health Prism → Authorizations → Authorization Criteria Lookup.
    Prior Authorization

    Follow eC PA and panel review workflows

    When a code is annotated 'eC PA' or 'Review in panels' providers must follow the payer's eC PA or panel review process and supply requested clinical evidence during the electronic review.

    • Follow Evicore guidance for clinical documentation and criteria submission via Priority Health Prism.
    • Panel-reviewed codes may require additional clinical justification beyond single-code claims.
    Documentation Required

    Include concise test description (genes/type of analysis) on PA/claim

    Provide a brief test description with claims or prior authorization requests (including gene names and type of analysis) as many CPT entries include a test description and the policy expects this supporting information.

    • Include gene names, panel size, and type of analysis (DNA/RNA/mitochondrial/cfDNA) in the PA or claim documentation.
    • For unlisted codes, include explanatory notes identifying the specific test.
    Documentation Required

    Document NIPT clinical rationale despite No PA for 81420

    Even when 81420 is designated 'No PA required', providers should still document counseling and the clinical indication to support medical necessity per the policy's prenatal testing section.

    • Document pre-test education and counseling, pregnancy type, and laboratory-validated gestational age.
    • Provide supporting documentation with the claim when requested.
    Billing Rule

    Attach explanatory notes when billing unlisted codes

    When billing unlisted codes (e.g., 81479, 81599, 84999) include explanatory notes identifying the specific test and the methodology; the policy requires explanatory notes to accompany claims for unlisted procedures.

    • Attach explanatory notes that identify the test name, method, genes/panels interrogated, and clinical rationale.
    • Failure to include explanatory notes may impede adjudication or result in denial.
    Documentation Required

    Provide explanatory notes with unlisted-code claims

    Unlisted codes such as 81599 and 84999 must be accompanied by explanatory documentation identifying the specific test when submitting claims.

    • Provide test name, lab alias, methodology, and clinical justification with the claim.
    • Use explanatory notes to clarify the billed service for adjudication.
    Prior Authorization

    Obtain PA for tests annotated 'eC PA'

    Providers must obtain prior authorization where tests are listed as 'eC PA'—the policy repeatedly instructs that tests marked eC PA require electronic prior authorization per the plan designations.

    • This operational requirement applies across CPT, PLA, and U-code entries annotated 'eC PA'.
    • Submit requisite clinical documentation and test details via Evicore/Priority Health Prism.
    Prior Authorization

    Use eC PA process for tests labeled 'eC PA'

    Tests designated 'eC PA' require electronic prior authorization; providers should use the electronic PA process to secure authorization prior to testing and claims submission.

    • This is an operational reminder repeated throughout the per-code listings.
    • Include diagnosis, prior testing, specimen type, and brief test description in the eC PA request.
    Prior Authorization

    Obtain eC PA before claims submission for eC PA tests

    When a test is labeled 'eC PA' the provider must obtain prior authorization through the electronic clinical prior authorization process before submitting a claim; failure to do so may result in denial.

    • Examples: multiple U-codes and PLA codes list eC PA—obtain PA via Evicore prior to performing the test.
    • Provide complete clinical justification and attach supporting reports as requested.
    Documentation Required

    Submit specimen source and report documentation with PA/claims

    Include specimen source and the laboratory report showing clinically significant findings when submitting documentation; many code descriptions specify specimen requirements (eg, plasma for cfDNA, tumor and normal blood/saliva for paired tumor-normal testing).

    • Examples: Signatera (0340U) requires prior tumor/germline NGS context; cfDNA assays request plasma specimen documentation.
    • Attach lab reports and specimen source documentation with PA requests and claims.
    Documentation Required

    Include required ICD‑10 when test coverage is diagnosis‑limited

    Provide the correct ICD‑10 diagnosis codes when coverage is diagnosis‑specific; certain tests (eg, 0471U CRCdx RAS kit) are covered only for listed ICD‑10 codes and claims should include the indicated diagnosis.

    • 0471U is covered only for colorectal cancer ICD‑10 codes C18.0–C18.9, C19, C20, C21.0–C21.8.
    • Verify and include the covered diagnosis code on the PA request and claim.
    Denial Risk

    Failure to obtain required eC PA may lead to denial

    Many tests labeled 'eC PA' require prior authorization; failure to obtain required PA through Evicore or the eC process may lead to denial or medical necessity review.

    • Obtain eC PA for codes annotated 'eC PA' before testing or billing.
    • If testing is urgent, notify Priority Health/Evicore per Evicore guidelines to avoid delays.
    Documentation Required

    Include specified diagnosis codes for diagnosis‑restricted tests

    When coverage for a test is limited to specific diagnoses (example: 86294 BTA Stat for specified bladder diagnoses), include the appropriate diagnosis code to support coverage.

    • 86294 is covered only for diagnoses C67.0–C67.9, D09.0, D49.4, and Z85.51.
    • Claims without the required diagnosis may be denied or returned for clarification.
    Billing Rule

    Attach explanatory notes for unlisted codes with claims

    Unlisted procedure codes (e.g., 81599, 84999, 88299, 89240, 88399) require explanatory notes identifying the specific test or procedure when billed; attach detailed explanatory documentation to the claim.

    • Explain the test methodology, genes/panels interrogated, clinical indication and lab performing the test.
    • Failure to include explanatory notes may delay processing or trigger denial.
    Denial Risk

    Denial risk if Evicore PA not obtained where required

    Failure to obtain prior authorization via Evicore for selected tests may result in claim denial or requirement for retrospective review; obtain PA before testing when codes are annotated as requiring Evicore authorization.

    • Evicore-managed tests include many codes in the 81105–81599 range and numerous U-codes; access Evicore via Priority Health Prism.
    • Denials are likely if required prior authorization is not obtained.
    Note

    Not Covered procedures: no PA required but voluntary authorization possible

    Procedures that are explicitly 'Not Covered' do not require prior authorization, but providers may submit voluntary authorization requests for a non‑coverage determination if desired; verify per-code coverage status before ordering.

    • Not Covered entries (per payer column) will be denied if billed under that plan.
    • Voluntary authorization can be requested for non‑coverage determination in selected cases.
    Denial Risk

    Panel combination denial risk — obtain PA for the code that requires it

    When multiple procedure codes within the 81105–81599 range are reported as part of a panel, all included procedure codes are subject to medical necessity review if any code requires prior authorization; obtain PA for the code that requires it to reduce panel combination denial risk.

    • If a multi-code panel contains any eC PA code, the entire panel may be reviewed.
    • Use the procedure code requiring PA to initiate the Evicore request to document the clinical rationale for the panel.
    Denial Risk

    Not Covered codes will be denied if billed under the listed plan

    Tests explicitly annotated 'Not Covered' in the per‑code listings will be denied if submitted for coverage under the listed plan(s); verify the Not Covered annotations in code columns prior to ordering.

    • Examples: selected single-gene and PLA codes annotated Not Covered for certain plans (eg, 81324 PMP22 Not Covered for Medicaid and Priority Medicare).
    • Do not expect reimbursement for codes marked Not Covered for the member's plan.
    Denial Risk

    Per-code 'Not Covered' annotations indicate high denial risk

    Some CPT and PLA codes are explicitly listed as 'Not Covered' for certain lines of business (Commercial, Medicaid, Priority Medicare); billing those codes for affected plans is likely to trigger denial—check the code-specific payer column.

    • Examples include 81324 (PMP22 duplication/deletion) and several U-codes shown as Not Covered in the per-code listings.
    • If a test is needed despite Not Covered status, consider submitting a voluntary non-coverage determination request as noted.
    Denial Risk

    Lack of required eC PA may trigger denial

    Tests labeled 'eC PA' in the policy require electronic clinical prior authorization; failure to obtain such authorization before testing or billing may result in denial.

    • This operational requirement applies across CPT, PLA, and U-code entries designated eC PA.
    • Obtain PA through Evicore/Priority Health Prism and include required clinical documentation.
    Denial Risk

    Obtain eC case review to avoid denials for eC PA codes

    Many tests require electronic case review (eC PA); failure to obtain electronic case review/prior authorization where indicated (most CPT entries list 'eC PA') may trigger claim denial.

    • Obtain eC PA for codes annotated 'eC PA' to avoid denials.
    • If uncertain, verify the code's per-plan annotation before testing.
    Denial Risk

    Not Covered tests are denial triggers when billed

    Tests explicitly labeled 'Not Covered' in the PLA/CPT/U-code entries (many listed examples) will be denied if submitted for coverage under the listed plan(s); providers should avoid billing those tests under those plans.

    • Examples include many PLA U-codes and select CPT codes annotated as Not Covered across plan columns.
    • Confirm member coverage and consider alternative testing or documentation if clinically necessary.
    Denial Risk

    Billing 'Not Covered' tests to the listed plan will likely be denied

    Tests listed as 'Not Covered' in the per-code entries will be denied if billed under the specified plan(s); providers should verify Not Covered status for the member's plan before ordering.

    • The policy lists many specific Not Covered codes (e.g., 0078U, 0086U, 0115U, 0152U).
    • Consider requesting individual case review if the test is investigational yet potentially beneficial.
    Denial Risk

    Routinely check Not Covered PLA code ranges to avoid denials

    Multiple contiguous PLA/CPT codes and ranges are explicitly marked 'Not Covered' in the policy (examples shown) and will be denied if billed under the listed plans; providers must check each code's plan column before ordering.

    • The 0181U–0200U range contains many red blood cell antigen genotyping tests marked Not Covered.
    • Avoid billing Not Covered PLA codes to the affected plans.
    Denial Risk

    Program‑specific 'Not Covered' status will trigger denials

    Tests listed as Not Covered for a given program (eg, Medicaid, Commercial, Priority Medicare) are subject to denial for that program when billed; verify program-specific status prior to performing the test.

    • Examples include PLA codes and U-codes with plan-level Not Covered annotations.
    • If clinically necessary, consider individual case review and prior plan approval when applicable.
    Denial Risk

    Explicit Not Covered tests are high-risk for denial

    Specific tests are explicitly marked Not Covered in the listings (examples include entries across chunks); providers should not expect reimbursement for those tests and billing them will likely result in denial.

    • Examples include 0279U–0281U (VWD assays) with mixed coverage and 0295U (DCISionRT) marked Not Covered.
    • Check the code-level annotation and plan column before ordering.
    Denial Risk

    Certain tests (e.g., 0328U) are Not Covered across plans — avoid billing

    Tests explicitly designated 'Not Covered' in the document (e.g., 0328U) are listed as Not Covered for Commercial, Medicaid, and Priority Medicare and will be denied if billed under those plans.

    • 0328U (definitive drug assay ≥120 drugs) is listed Not Covered across plans.
    • Do not bill these codes to the listed plans; consider alternative testing or individual case review.
    Note

    Verify OOS vs eC PA distinctions to determine PA need

    Some tests are designated OOS for eC (No PA required) while others are eC PA; verify whether a code is OOS versus eC PA as this affects whether prior authorization is required and whether denials may occur without PA.

    • Example: 0402U (Abbott Alinity m STI Assay) is OOS for eC — No PA required.
    • Other tests listed as eC PA will be denied if PA is not obtained.
    Denial Risk

    Billing Not Covered tests to listed plans will result in denials

    Tests flagged as 'Not Covered' (multiple U-codes and CPT entries are examples) will be denied when billed under the listed plans; providers should verify coverage status and consider individual case review if clinically necessary.

    • Examples include 0425U/0426U/0429U/0463U/0490U–0492U marked Not Covered.
    • If a test is clinically critical, submit an individual case review request per policy (requires prior plan approval).
    Denial Risk

    Not Covered annotation indicates likely claim denial for that plan

    Tests listed as 'Not Covered' for a given plan (Commercial, Medicaid, Priority Medicare) are subject to denial if billed to that plan; verify plan column and do not bill Not Covered tests to those plans.

    • Examples include multiple PLA/U-codes annotated Not Covered for specific plans.
    • Consider voluntary authorization or individual case review when appropriate.
    Denial Risk

    OOS-for-eC 'Not Covered' codes are denial risks

    Codes explicitly listed as 'OOS for eC - Not Covered' in the excerpt (examples provided) may be denied if submitted for payment under the affected plans; verify the OOS/Not Covered listing before ordering.

    • Examples: 83006, 83951, 86152, 86153, 86300, 86305, 86352 appear as OOS for eC - Not Covered.
    • Do not submit these codes for payment under plans where they are listed Not Covered.
    Denial Risk

    Investigational/experimental tests require prior plan approval for exceptions

    Coverage determinations for experimental, investigational, or unproven tests may be denied unless an exception is granted via individual case review; such exceptions require prior plan approval and adjudication by a Priority Health medical director or clinical pharmacist.

    • Individual case review can allow coverage for investigational yet promising care, but requires prior plan approval.
    • Submit requests with full clinical justification and supporting evidence for consideration.

    Additional U‑code examples explicitly listed as Not Covered include 0078U, 0086U, 0115U, 0152U, 0177U and a broad set of red blood cell antigen genotyping PLA codes (eg, 0180U–0187U). These entries are annotated 'Not Covered' in the coding tables for the listed plans.

    The coding tables contain a range of PLA and proprietary test codes marked in red as Not Covered for one or more plans. Providers must consult the per‑code payer column — tests flagged as 'Not Covered' will be denied if billed under that plan without an approved exception.

    The document includes plan‑specific examples of tests that are not covered or have restricted coverage. For instance, several U‑codes in the 0328U–0336U and 0371U–0378U ranges are annotated as Not Covered for Commercial, Medicaid, and Priority Medicare; consult the coding listing for the exact U‑code statuses and plan columns.

    Not covered entries include specific U‑codes such as 0328U, 0330U, 0371U among others shown in the code tables. These codes are annotated 'Not Covered' across the indicated plans and will be denied if submitted for payment without an approved exception.

    This portion of the coding listing shows additional U‑codes annotated Not Covered, for example 0425U, 0426U, 0429U, 0463U, 0490U–0492U. Providers should verify each code’s payer column when determining coverage and prior authorization needs.

    Several proprietary tests are explicitly noted as Not Covered for one or more plan types. Examples listed include 0491U, 0492U, 0500U, 0511U and others; check the per‑code plan designation before ordering or submitting claims.

    A subset of commonly used CPT and other test codes are designated OOS for eC — Not Covered in the excerpt (for example, 83006, 83951, 86152, 86153, 86300, 86305, 86352), indicating those services are out‑of‑scope for the electronic prior authorization workflow and are not covered per the payer columns.

    As a general principle, tests that are experimental, investigational, or unproven are excluded from coverage unless an exception is approved through individual case review. Requests for exceptions require prior plan approval and are reviewed by a Priority Health medical director or clinical pharmacist; supporting documentation must show substantial justification for coverage of an investigational test.

    Evicore case review may allow exceptions for tests that are otherwise investigational where sufficient supporting evidence and documentation are provided. Any exception requires prior approval and is subject to review by the payer’s clinical reviewers.

    Definition — Genetic testing
    DefinitionGenetic testing: analysis of human DNA, RNA, chromosomes, proteins, or metabolites to detect alterations related to heritable or acquired disorders; includes direct testing, linkage testing, biochemical testing, and cytogenetic testing for diagnosis, prevention, or treatment.
    Clinical purposeResults are reported to providers or patients to support individual patient care decisions (diagnosis, prevention, treatment).
    Modalities includedIncludes molecular (DNA/RNA), chromosomal, protein, and metabolite analyses performed in clinical laboratories.
    Definition — WGS/WES/rWGS
    WGS/WESWhole genome sequencing (WGS) determines an individual's entire DNA sequence; whole exome sequencing (WES) determines the protein-coding portion (exome).
    rWGSRapid whole genome sequencing (rWGS) is a high-speed form of WGS used for expedited diagnostic evaluation (document notes inpatient pediatric use criteria).
    Clinical roleWGS/WES/rWGS are diagnostic tools for unexplained constitutional/heritable disorders; rWGS shortens analysis time and is evolving clinically.
    Definition — eC PA (electronic clinical prior authorization)
    DefinitioneC PA (electronic clinical prior authorization): the payer's electronic prior authorization process referenced in code annotations indicating prior authorization is required before coverage.
    Where usedMany CPT/PLA codes in this policy are designated 'eC PA' requiring electronic prior authorization for Commercial, Medicaid, and Priority Medicare unless otherwise noted.
    Access pointProviders obtain prior authorization via Evicore/Priority Health electronic workflows (Priority Health Prism).
    Definition — Review in panels
    Definition'Review in panels' indicates the payer evaluates the code within a multi-gene panel review or clinical review process rather than as an individually preapproved standalone test.
    ImplicationSingle-code reporting may be covered without PA in some cases, but panel review or PA may be required if combined with codes that require authorization.
    ExamplesMultiple CPT codes (eg, certain HLA and single-gene tests) are marked 'Review in panels' in the code listing.
    Definition — Not Covered (usage in doc)
    Definition'Not Covered': payer-designated tests that the plan will not reimburse under the specified plan; submission will result in denial when billed under that plan.
    Plan-specificMany 'Not Covered' annotations apply to specific lines (Commercial, Medicaid, Priority Medicare) — verify per-code payer column.
    ExamplesExamples in the listing include multiple U-codes and CPT entries explicitly labeled Not Covered (see code entries).
    Definition — eC PA designation usage
    UsageThe 'eC PA' designation in code listings signals tests that require electronic prior authorization; providers must submit PA requests demonstrating medical necessity before testing or billing.
    ExamplesNumerous CPT and U-codes (eg, many 81xxx and U-code entries) are annotated 'eC PA' across Commercial, Medicaid, and Priority Medicare columns.
    Process noteFailure to obtain required eC PA via Evicore/Priority Health Prism may result in claim denial or review.
    Definition — Review in panels designation usage
    Usage'Review in panels' is applied to codes that the payer evaluates within panel-level review; coverage determinations rely on panel criteria rather than single-code automatic coverage.
    Implication for panelsCodes marked 'Review in panels' may not require separate PA if reported alone but are subject to panel review or PA when combined with codes requiring authorization.
    ExamplesSeveral gene sequencing CPT codes and HLA typing codes carry the 'Review in panels' annotation in the code table.
    Definition — Genomic sequence analysis panel
    DefinitionGenomic sequence analysis panel: a multi-gene panel testing approach specified for clinical conditions; many panel codes require a minimum number of genes and inclusion of specific genes for that indication.
    MinimumsPanel CPT codes include minimum gene counts (eg, some panels require >=15 genes; others specify larger minima such as >=51 or >=60 genes depending on indication).
    ExamplesDisease-specific panels include hereditary cancer, hearing loss, mitochondrial, peripheral neuropathy, and tumor panels with defined gene content requirements.
    Definition — Exome/Genome codes descriptions (81415/81425 etc.)
    81415/8142581415 = Exome sequence analysis; 81425 = Genome sequence analysis (primary exome/genome for unexplained constitutional/heritable disorders).
    Companion codesCompanion comparator codes 81416/81426 denote each comparator exome/genome (eg, parents/siblings) listed separately; 81417/81427 denote re-evaluation of prior exome/genome sequences.
    Unlisted molecular pathology81479 is used for molecular tests not otherwise specified and requires explanatory notes identifying the specific test when billed.
    Definition — Whole mitochondrial genome
    DefinitionWhole mitochondrial genome (81460): genomic sequence analysis of the entire mitochondrial genome with heteroplasmy detection for mitochondrial disorders (eg, MELAS, MERFF, NARP, LHON).
    IndicationsUsed for suspected mitochondrial disorders presenting with neurologic, ophthalmologic, myopathic, or multisystem phenotypes.
    Coverage note81460 is designated eC PA in the code listing (coverage managed via eC PA process).
    Definition — Unlisted molecular pathology (81479) billing requirements
    DefinitionUnlisted molecular pathology (81479): procedural code for molecular tests not otherwise specified; explanatory notes identifying the specific test must accompany the claim.
    Claim requirementClaims using 81479 (and other unlisted codes like 81599/84999) must include explanatory documentation describing the specific test performed.
    Prior authorization81479 entries in the policy are annotated 'eC PA' indicating prior authorization is required when listed.
    Definition — eC PA (electronic check prior authorization) usage in code listings
    Definition'eC PA' in code listings also appears as 'electronic check prior authorization' indicating the test requires prior authorization via the payer's electronic workflow.
    Where seenNumerous CPT and proprietary U-code entries are annotated as requiring eC PA in the code tables (see listed codes).
    Provider actionProviders must submit electronic prior authorization requests per the eC PA process prior to testing/billing when code is annotated.
    Definition — OOS (out of scope) meaning
    DefinitionOOS (Out of Scope): indicates a code is out-of-scope for the electronic prior authorization (eC) process and no prior authorization is required for that code under the specified plan.
    ImplicationOOS entries may still have coverage determinations (Covered/Not Covered) but do not require eC PA under the indicated product column.
    ExamplesSeveral codes (eg, 0003U Overa - OVA1 Next Generation; 0402U STI assay) are noted OOS for eC - No PA required in the listings.
    Definition — eC PA (electronic claim with PA) usage
    Definition'eC PA' as 'electronic claim with prior authorization' denotes that the code is covered only when prior authorization is obtained via the electronic claims/prior authorization workflow.
    Provider requirementProviders must initiate the PA using the procedure code that triggers Evicore/Priority Health portal access for authorization.
    Coverage implicationWithout eC PA, claims for codes annotated as such may be denied or subject to review.
    Definition — Not Covered meaning in listings
    Definition'Not Covered' in code listings indicates the payer will not reimburse the test for the specified plan(s); such tests when billed will be denied under that plan.
    DocumentationThe code table shows plan‑level 'Not Covered' annotations (Commercial, Medicaid, Priority Medicare) — verify per-code entry.
    ExamplesMultiple CPT and U-codes are explicitly labeled 'Not Covered' in the policy (see code groups).
    Definition — OOS for eC - No PA required
    DefinitionOOS for eC - No PA required: indicates the test is out of scope for the electronic prior authorization process and no eC PA is required; coverage still depends on product/plan terms.
    Priority Medicare examplesSeveral Genomic Unity entries (eg, 0234U MECP2; 0235U PTEN; 0236U SMN1/2) are marked OOS for eC - No PA required for Priority Medicare.
    ActionEven when OOS for eC, providers should confirm plan coverage rules and submit documentation as required for claims.
    Definition — eC PA designation reiteration
    ReiterationThe 'eC PA' notation is used throughout code entries to denote tests that require evidence-based clinical prior authorization for Commercial, Medicaid, and Priority Medicare unless otherwise indicated.
    Provider implicationObtain electronic prior authorization via Evicore/Priority Health Prism for tests annotated eC PA to avoid denials.
    Common test typesMany oncology, cfDNA, reproductive, and specialty genomic tests are labeled eC PA in the listings.
    Definition — OOS for eC - No PA required (Priority Medicare examples)
    DefinitionOOS for eC - No PA required (Priority Medicare examples): certain proprietary Genomic Unity and other entries are out of scope for eC and require no PA under Priority Medicare column.
    Examples0234U (MECP2), 0235U (PTEN), 0236U (SMN1/2), 0237U (Cardiac Ion Channelopathies) are shown OOS for eC - No PA required for Priority Medicare.
    Verify per-codeProviders must check the specific code column for Priority Medicare to confirm OOS/No PA status.
    Definition — eC PA notation used across document
    Notation usageThe eC PA notation appears repeatedly across CPT and U-code listings to indicate electronic clinical prior authorization is required for coverage decisions.
    ScopeApplies to many proprietary U-codes and CPT panels for oncology, rare disease, transplant, and reproductive testing in the code tables.
    Provider stepFollow Evicore electronic prior authorization process when 'eC PA' is indicated to secure coverage prior to testing.
    Definition — OOS for eC annotation meaning
    DefinitionOOS for eC annotation means the code does not require eC prior authorization ('No PA required') under the listed plan column, but coverage may still be limited by plan terms.
    ExamplesEntries across U-code and CPT tables show OOS for eC with 'No PA required' for specific tests (eg, 0154U/0155U FGFR3/PIK3CA kits; 0279U/0280U VWF assays).
    Claim cautionEven when OOS, providers should include required documentation to support medical necessity per general policy.
    Definition — eC PA (additional references)
    Additional referencesThe eC PA designation is also applied to many higher‑complexity U‑code tests (eg, 0572U, 0575U, 0582U) indicating prior authorization is required across lines of business.
    Provider noteUse Evicore/Priority Health Prism to request eC PA for listed U-codes requiring authorization.
    Examples0575U (HepatoTrack miRNA), 0582U (rapid WGS) are shown with eC PA in code entries.
    Definition — OOS for eC - No PA required (additional references)
    Additional OOS notesMultiple entries indicate 'OOS for eC - No PA required' for Priority Medicare for select tests; this designation means no eC prior authorization is required for that product but coverage status may differ for other plans.
    ExamplesGenomic Unity single-gene entries and select red cell antigen tests show OOS for eC - No PA required under Priority Medicare columns.
    ActionConfirm plan-level OOS annotations before ordering to determine whether PA is required elsewhere.
    Definition — cfDNA uses (tumor/fetal)
    DefinitioncfDNA (cell-free DNA) use: cell-free DNA analysis is used for noninvasive fetal testing (NIPT) and for noninvasive tumor testing (liquid biopsy) as described in multiple code entries.
    ApplicationsUsed for fetal aneuploidy screening (eg, 81420) and for plasma-based tumor genomic profiling (multiple U-codes and CPT panel codes).
    Coverage distinctionsSome cfDNA fetal tests (eg, 81420) are No PA required; many oncology cfDNA panels are eC PA—verify per-code listing.
    Definition — OOS for eC meaning (no PA required)
    DefinitionOOS for eC (Out Of Scope for electronic criteria): indicates the code does not require prior authorization in the eC system per the listing (No PA required for commercial/other plans as noted).
    ExamplesCytogenetics and many pathology CPT codes (eg, 88267, 88269, 88271–88275) are shown OOS for eC - No PA required.
    Provider implicationWhen codes are OOS for eC, providers should still follow plan documentation requirements for claims submission.
    Definition — Rapid Whole Genome Sequencing code definition (0582U) and other code examples
    Rapid WGS code0582U: Rapid whole genome DNA sequencing for single-nucleotide variants, indels, copy number variations from blood/saliva/tissue; listed as eC PA for Commercial, Medicaid, Priority Medicare.
    Comparator code example0583U: Rapid whole genome comparator sequencing for family member; listed as eC PA and billed separately as an add-on/comparator.
    Other code examples0585U: large cfDNA plasma panel (521 genes) listed as eC PA; other high-complexity U-codes are similarly annotated.
    Some CPT entries specify exon- or codon-level coverage (eg, KRAS codons 12/13/exon2; NRAS exon2/exon3); refer to code description for exact variant coverage.
    Use in authorizationThese variant/exon specifications are cited in code descriptions and inform medical necessity/authorization reviews.
    Minimum gene counts and specific gene inclusions per panel code
    Minimum gene countsMany panel CPT codes specify minimum gene counts and required gene inclusions per indication (eg, 81410 min 9 genes; 81419 epilepsy list; 81430 min 60 genes; 81440 min 100 genes).
    Panel-specific listsSome panels list required genes by name (eg, 81410 includes FBN1,TGFBR1,TGFBR2,COL3A1,MYH11,ACTA2,SLC2A10,SMAD3,MYLK).
    Authorization impactPanel minimums and required gene inclusions are used to determine whether a submitted test meets the CPT panel definition for coverage/PA.
    Peripheral neuropathy panel gene count requirement (>=5 genes)
    Peripheral neuropathy panelHereditary peripheral neuropathies panel (81448) must include sequencing of at least 5 peripheral neuropathy-related genes (>=5 genes).
    ExamplesPolicy cites peripheral neuropathy-related gene examples used in panels (see code description for gene list).
    Coverage notePanel must meet the minimum gene count and include relevant genes to satisfy coverage requirements.
    XLID panel gene count (>=60 genes)
    XLID panel requirementX-linked intellectual disability panels (81470/81471) must include sequencing or duplication/deletion analysis of at least 60 genes (>=60 genes).
    Gene examplesExamples of included XLID genes: ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, SLC16A2.
    Coverage implicationPanels not meeting the 60-gene threshold may not meet the CPT panel definition for coverage.
    Large panels for solid organ/hematolymphoid indications (>=51 genes)
    Large panels thresholdSolid organ or hematolymphoid neoplasm panels of 51 or more genes (eg, 81455/81456) are defined as large panels (>=51 genes).
    Content scopeThese large panels interrogate sequence variants, CNVs, rearrangements, isoform/mRNA expression as applicable per CPT description.
    AuthorizationSuch large panels are annotated eC PA and require electronic prior authorization per code listing.
    Genomic sequence analysis smaller panels example (>=15 genes)
    Smaller genomic panelsCertain genomic sequence analysis panels are defined with minimums of >=15 genes (eg, 81443 and other disease-specific smaller panels).
    Example usesUsed for inherited metabolic or syndrome-specific testing where a smaller gene set is appropriate per CPT description.
    Coverage noteMeet the CPT-specified gene-count and content to qualify under the panel code for authorization/coverage.
    Genes interrogated examples per test
    Genes interrogated examplesExamples: NSCLC panel (0022U) = 23 genes; FoundationOne CDx (0239U) = 311+ genes; MSK-IMPACT (0048U) = 468 genes; ThyroSeq (0287U) = 112 genes.
    ImplicationDocument lists panel sizes and representative gene counts to support identification of appropriate test code and prior authorization review.
    Provider actionSelect test code matching the laboratory's gene content and provide documentation to meet PA criteria.
    Panel gene counts examples (FoundationOne Liquid CDx, Guardant360, PGDx elio)
    Panel examplesFoundationOne Liquid CDx = 311+ genes (0239U); Guardant360 = 55-74 genes (0242U/0326U variants); PGDx elio = 505 genes (0250U).
    Other countsOncotype MAP = 257 genes (0244U) and many other U-code entries specify gene counts in the code descriptions.
    AuthorizationThese panels are annotated eC PA and require electronic prior authorization per listing.
    Panel gene counts (examples: 15 genes for 0268U; 112 genes for 0287U; 83+ genes for 0326U)
    Panel gene count examplesExamples include 15 genes for 0268U (aHUS panel), 112 genes for 0287U (ThyroSeq), 83+ genes for 0326U (Guardant/related entries).
    ContextPolicy provides many per-code gene counts to guide correct code selection and PA documentation.
    Provider tipConfirm the lab's reported gene count matches the CPT/U-code description when requesting PA.
    Panel gene counts and reported thresholds (examples)
    Reported thresholdsExamples: 0334U targeted tumor panel >=84 genes; 0391U = 437 genes; 0379U = 523 DNA/55 RNA genes; 0400U expanded carrier screen = 145 genes.
    Variation across testsGene counts and assay complexity vary widely by test; many entries include exact counts or ranges to aid coverage decisions.
    AuthorizationHigh gene-count panels are typically annotated eC PA in the policy.
    Diagnosis list threshold — example ICD-10 range required for 0471U
    Diagnosis restriction0471U (CRCdx RAS Mutation Detection Kit) coverage is limited to specified ICD-10 diagnoses: C18.0–C18.9, C19, C20, C21.0–C21.8; claims must include an allowed diagnosis code.
    Provider actionInclude the required ICD-10 code(s) on claims to meet the diagnosis‑specific coverage requirement for 0471U.
    Plan variance0471U is Covered for certain diagnoses under Commercial plans but Not Covered for Medicaid per the listing; Priority Medicare shows Covered.
    Number of differentially methylated regions — examples for methylation assays
    Methylation region countsPolicy lists numbers of differentially methylated regions for methylation assays: examples include >2500 DMRs (Shield), >20,000 DMRs (Guardant Reveal), and 6626 alterations (EarlyDx MethylScan HCC).
    Test examplesMethylation-based cfDNA assays and tumor methylation panels include reported DMR counts in their code descriptions to describe assay scope.
    Coverage noteThese assay characteristics are noted in code entries and used in PA/review processes.
    Cell count analysis thresholds for preimplantation genetic testing examples
    Cell count thresholdsCytogenetic FISH/cell analyses include cell‑count reporting thresholds by code (examples: analyze 3-5 cells, 10-30 cells, 25-99 cells, 100-300 cells depending on code).
    CodesCodes 88272–88275 correspond to in-situ hybridization cell count ranges (3-5, 10-30, 25-99, 100-300 cells respectively) and are OOS for eC - No PA required.
    Provider documentationEnsure the laboratory report documents the cell count analyzed to support claim coding and coverage.